MCID: ORL011
MIFTS: 56

Oral Cancer

Categories: Rare diseases, Oral diseases, Cancer diseases

Aliases & Classifications for Oral Cancer

MalaCards integrated aliases for Oral Cancer:

Name: Oral Cancer 50 52 41 3
Lip and Oral Cavity Carcinoma 69
Malignant Neoplasm of Mouth 69

Classifications:



Summaries for Oral Cancer

MedlinePlus : 41 oral cancer can form in any part of the mouth. most oral cancers begin in the flat cells that cover the surfaces of your mouth, tongue, and lips. anyone can get oral cancer, but the risk is higher if you are male, use tobacco, drink lots of alcohol, have hpv, or have a history of head or neck cancer. frequent sun exposure is also a risk factor for lip cancer. symptoms of oral cancer include white or red patches in your mouth a mouth sore that won't heal bleeding in your mouth loose teeth problems or pain with swallowing a lump in your neck an earache tests to diagnose oral cancer include a physical exam, endoscopy, biopsy, and imaging tests. oral cancer treatments may include surgery, radiation therapy, and chemotherapy. some patients have a combination of treatments. nih: national cancer institute

MalaCards based summary : Oral Cancer, also known as lip and oral cavity carcinoma, is related to prostate cancer and lung cancer, and has symptoms including halitosis and snoring. An important gene associated with Oral Cancer is ORAOV1 (Oral Cancer Overexpressed 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Drug metabolism - cytochrome P450. The drugs Iron and Oxaliplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and brain, and related phenotypes are cardiovascular system and growth/size/body region

NIH Rare Diseases : 50 oral cancer includes cancers of the mouth, lips, and oropharynx (the part of the throat at the back of the mouth). most cases are designated as squamous cell carcinomas because they begin in the flat cells (squamous cells) that cover the surfaces of the mouth, tongue, and lips. about 42,000 individuals in the united stated are diagnosed with oral cancer each year. most cases occur in people over age 40. men are twice as likely to be affected as women. the use of alcohol and/or tobacco is associated with approximately 75 percent of oral cancers. other risk factors include hpv, a sexually transmitted disease; increasing age; sun exposure; and a poor diet. treatment for oral cancer may include surgery, radiation therapy, chemotherapy, or targeted therapy. last updated: 6/21/2016

Wikipedia : 72 Oral cancer, also known as mouth cancer, is a type of head and neck cancer and is any cancerous tissue... more...

Related Diseases for Oral Cancer

Diseases related to Oral Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 203)
id Related Disease Score Top Affiliating Genes
1 prostate cancer 27.1 CASP3 CCND1 CDH1 EGFR GSTM1 MMP2
2 lung cancer 25.5 CASP3 CCND1 CDH1 CDKN2A CYP1A1 EGFR
3 oral submucous fibrosis 11.0
4 oral lichen planus 11.0
5 pediatric infratentorial ependymoma 10.8 EGFR TP53
6 basedow's coma 10.8 CYP1A1 GSTT1
7 renal pelvis urothelial papilloma 10.8 CDH1 TP53
8 cervical adenoid cystic carcinoma 10.8 CDKN2A TP53
9 facial arteriovenous malformation 10.7 MMP2 MMP9
10 skeletal tuberculosis 10.7 CCND1 CDKN2A
11 diffuse mesangial sclerosis 10.7 CDH1 GSTM1 GSTT1
12 familial short qt syndrome 10.7 MMP2 MMP9
13 tendon sheath lipoma 10.7 PTGS2 TP53
14 hip subluxation 10.7 CCND1 EGFR TP53
15 geographic tongue 10.6
16 lacrimal gland mucoepidermoid carcinoma 10.6 CDH1 EGFR TP53
17 rhizomelic chondrodysplasia punctata, type 3 10.6 CASP3 TP53
18 ulnar neuropathy 10.6 CDH1 MMP2 MMP9
19 dental caries 10.6 CDH1 MMP2 TP53
20 nasal cavity disease 10.6 CDH1 MMP2 TP53
21 acquired hemangioma 10.6 EGFR MMP2 MMP9
22 bladder squamous cell carcinoma 10.6 CCND1 CDKN2A TP53
23 lung papillary adenocarcinoma 10.6 CDH1 MMP2 MMP9
24 retroperitoneal sarcoma 10.6 CASP3 GSTM1 GSTT1
25 kleptomania 10.6 MMP2 MMP9
26 multiple carboxylase deficiency 10.6 CDKN2A EGFR TP53
27 cleft lip palate dysmorphism kumar type 10.6 CCND1 EGFR TP53
28 mycetoma 10.6 CCND1 GSTM1 GSTT1 TP53
29 leucocyte adhesion defect 10.6 MMP2 MMP9
30 molluscum contagiosum 10.6 CDKN2A EGFR TP53
31 immunodeficiency 27b, mycobacteriosis, ad 10.6 CDH1 MMP9 PTGS2
32 acute monocytic leukemia 10.6 CDKN2A GSTM1 GSTT1
33 extrahepatic cholestasis 10.6 ANO1 KRT13
34 xanthogranulomatous cholecystitis 10.6 CASP3 MMP2 MMP9
35 unilateral retinoblastoma 10.6 CCND1 CDKN2A TP53
36 fallopian tube leiomyosarcoma 10.6 CDH1 CDKN2A TP53
37 pharynx cancer 10.6 CCND1 CDKN2A TP53
38 cecum adenocarcinoma 10.6 CDKN2A EGFR TP53
39 ovarian cystadenocarcinoma 10.6 CASP3 GSTM1 GSTT1
40 rectum kaposi's sarcoma 10.6 EGFR PTGS2 TP53
41 myxedema 10.6 CDKN2A EGFR TP53
42 pulmonary fibrosis, idiopathic susceptibility 10.5 CDH1 CYP1A1 GSTM1 GSTT1
43 bullous keratopathy 10.5 CYP1A1 KRT19 TP53
44 colon squamous cell carcinoma 10.5 CDKN2A MMP2 MMP9
45 villous adenocarcinoma 10.5 CDKN2A PTGS2 TP53
46 peritoneal serous adenocarcinoma 10.5 CDH1 KRT19 TP53
47 esophagus squamous cell carcinoma 10.5 CDKN2A PTGS2 TP53
48 measles 10.5 CYP1A1 EGFR GSTM1 GSTT1
49 brachial amelia, forebrain defects and facial clefts 10.5 CCND1 CDKN2A PTGS2
50 split hand split foot nystagmus 10.5 CDKN2A TP53

Graphical network of the top 20 diseases related to Oral Cancer:



Diseases related to Oral Cancer

Symptoms & Phenotypes for Oral Cancer

UMLS symptoms related to Oral Cancer:


halitosis, snoring

MGI Mouse Phenotypes related to Oral Cancer:

44 (show all 20)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.4 CDH1 CCND1 ANO1 CASP3 KRT19 CYP1A1
2 growth/size/body region MP:0005378 10.38 CASP3 CDH1 CDK2AP1 CCND1 ANO1 CYP1A1
3 mortality/aging MP:0010768 10.37 CASP3 CDH1 CCND1 ANO1 CYP1A1 KRT19
4 cellular MP:0005384 10.32 CCND1 CASP3 CDH1 EGFR CDKN2A CDK2AP1
5 digestive/alimentary MP:0005381 10.27 CASP3 CDH1 CCND1 KRT19 EGFR CDKN2A
6 immune system MP:0005387 10.26 CCND1 CASP3 CDH1 EGFR CDKN2A CYP1A1
7 endocrine/exocrine gland MP:0005379 10.25 CASP3 CDH1 CCND1 CDKN2A CYP1A1 EGFR
8 integument MP:0010771 10.21 CASP3 CDH1 CCND1 ANO1 KRT19 EGFR
9 nervous system MP:0003631 10.21 CASP3 CCND1 ANO1 CDKN2A EGFR PTGS2
10 embryo MP:0005380 10.16 CDH1 EGFR CDKN2A CDK2AP1 PTGS2 KRT19
11 muscle MP:0005369 10.13 CASP3 ANO1 EGFR CDKN2A MMP9 MMP2
12 craniofacial MP:0005382 10.12 CCND1 CASP3 EGFR CDK2AP1 MMP2 TP53
13 neoplasm MP:0002006 10.11 CDH1 CCND1 KRT19 EGFR CDKN2A MMP9
14 normal MP:0002873 10.02 CCND1 CDH1 EGFR CYP1A1 MMP2 PTGS2
15 no phenotypic analysis MP:0003012 10.01 CASP3 CDH1 EGFR CDKN2A CYP1A1 PTGS2
16 reproductive system MP:0005389 9.96 CASP3 CDH1 CCND1 CDKN2A KRT19 EGFR
17 renal/urinary system MP:0005367 9.87 CASP3 ANO1 EGFR PTGS2 MMP9 TP53
18 respiratory system MP:0005388 9.85 CASP3 CCND1 ANO1 EGFR CDKN2A MMP9
19 skeleton MP:0005390 9.73 CASP3 CCND1 ANO1 KRT19 EGFR CDKN2A
20 vision/eye MP:0005391 9.28 CASP3 CCND1 CDKN2A EGFR MMP2 PTGS2

Drugs & Therapeutics for Oral Cancer

Drugs for Oral Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1529)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
2
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
3
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1 103-90-2 1983
4
Pravastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 81093-37-0 54687
5
Sucralfate Approved Phase 4,Phase 3 54182-58-0
6
Amiodarone Approved, Investigational Phase 4,Phase 3 1951-25-3 2157
7
Erythromycin Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 114-07-8 12560
8
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1 616-91-1 12035
9
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
10
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
11
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 6740-88-1 3821
12
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 59467-70-8 4192
13
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
14
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2 2180-92-9, 38396-39-3 2474
15
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 51-43-4 5816
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 437-38-7 3345
17
Ketorolac Approved Phase 4,Phase 2 74103-06-3, 66635-83-4 3826
18
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 57-27-2 5288826
19
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 2078-54-8 4943
20 Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1
21
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 169590-42-5 2662
22 Parecoxib Approved Phase 4,Phase 3 198470-84-7
23
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2 27203-92-5 33741
24
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-78-2 2244
25
Pantoprazole Approved Phase 4,Phase 2,Phase 1 102625-70-7 4679
26
Ticlopidine Approved Phase 4 55142-85-3 5472
27
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
28
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
29
Ethiodized oil Approved Phase 4,Phase 2,Phase 3 8008-53-5
30
Sorafenib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 284461-73-0 216239 406563
31
Levonorgestrel Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 797-63-7, 17489-40-6 13109
32
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2 71-58-9
33
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
34
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
35
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 150399-23-8, 137281-23-3 446556 60843
36
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 170729-80-3 151165 6918365
37
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
38
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 172673-20-0 219090
39
Palonosetron Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135729-61-2, 119904-90-4, 135729-56-5 148211
40
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
41
Nicotine Approved Phase 4,Phase 3,Phase 2 54-11-5 942 89594
42
Hydromorphone Approved, Illicit Phase 4,Phase 3,Phase 1 466-99-9 5284570
43
Copper Approved Phase 4,Phase 2,Phase 1 7440-50-8 27099
44
Molybdenum Approved Phase 4,Phase 2,Phase 1 7439-98-7 185498
45
Selenium Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 7782-49-2
46
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
47
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
48
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
49
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
50
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953

Interventional clinical trials:

(show top 50) (show all 9730)

id Name Status NCT ID Phase Drugs
1 Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Unknown status NCT00172965 Phase 4
2 rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors Unknown status NCT00902083 Phase 4 p53 gene with surgery;p53 with chemotherapy;p53 gene therapy
3 Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
4 Early Jejunostomy Nutrition Minimizes Time to Chemotherapy Unknown status NCT01766765 Phase 4
5 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
6 Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia Unknown status NCT02243735 Phase 4 Ferrous fumarate;ferric(III)carboxymaltose
7 Paracetamol for Cancer Pain Unknown status NCT01313247 Phase 4 paracetamol;placebo tablets
8 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
9 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
10 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
11 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
12 ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial Unknown status NCT02016807 Phase 4
13 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4 Amiodarone
14 p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage Unknown status NCT00894153 Phase 4 chemotherapy plus p53;chemotherapy
15 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
16 THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS Unknown status NCT02241876 Phase 4 N-acetylcysteine
17 Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer Unknown status NCT01049295 Phase 4
18 Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients Unknown status NCT00772824 Phase 4
19 A Clinical Trial of Oral Midazolam Plus Oral Ketamine for Sedation During Laceration Repair Unknown status NCT01470157 Phase 4 Ketamine;Normal Saline
20 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
21 Serratus Anterior Plane Block Versus Paravertebral Block for Postmastectomy Analgesia Unknown status NCT02103946 Phase 4
22 First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients Unknown status NCT01646450 Phase 4 Icotinib
23 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
24 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
25 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
26 A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia Unknown status NCT01074892 Phase 4 Provera (medroxyprogesterone/progestin);Provera (medroxyprogesterone)
27 Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
28 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
29 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
30 Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery Unknown status NCT00790140 Phase 4
31 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
32 Palonosetron Associated to Aprepitant in Prophylaxis of PONV Unknown status NCT02431286 Phase 4 Aprepitant;Placebo;Dexamethasone
33 Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
34 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
35 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
36 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients Completed NCT01283906 Phase 4
37 An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain Completed NCT00766831 Phase 4 Hydromorphone
38 An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer Completed NCT01006356 Phase 4 Hydromorphone HCl OROS
39 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
40 Absorption of Orally Ingested Phosphate in Refeeding Syndrome Completed NCT02880072 Phase 4
41 Enteral Nutrition Support in Children and Adolescents With Cancer Completed NCT01426750 Phase 4
42 Enteral Nutrition in Cancer Patients Completed NCT01304446 Phase 4
43 Enteral Nutrition in Cancer Patient Completed NCT01302509 Phase 4
44 Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer Completed NCT01989845 Phase 4 Rivaroxaban
45 Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer Completed NCT02074137 Phase 4 CABAZITAXEL XRP6258;Prednisone;Prednisolone
46 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
47 A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer Completed NCT02581423 Phase 4 Capecitabine
48 Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery Completed NCT00571155 Phase 4 levetiracetam
49 Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients Completed NCT01621100 Phase 4 OROS hydromorphone
50 Mouth Care Regimes During Radiotherapy Completed NCT00138827 Phase 4 Biotene (mouth care)

Search NIH Clinical Center for Oral Cancer

Genetic Tests for Oral Cancer

Anatomical Context for Oral Cancer

MalaCards organs/tissues related to Oral Cancer:

39
Lung, Prostate, Brain, Myeloid, Liver, Bone, Thyroid

Publications for Oral Cancer

Articles related to Oral Cancer:

(show top 50) (show all 1240)
id Title Authors Year
1
Screening and early detection of oral cancer: current controversies. ( 28937121 )
2017
2
MiR-214 regulates oral cancer KB cell apoptosis through targeting RASSF5. ( 28290615 )
2017
3
Withaferin A Induces Oxidative Stress-Mediated Apoptosis and DNA Damage in Oral Cancer Cells. ( 28936177 )
2017
4
Assessment of the quality of life of the patients with treated oral cancer in Iran. ( 28948377 )
2017
5
Vimentin regulates differentiation switch via modulation of keratin 14 levels and their expression together correlates with poor prognosis in oral cancer patients. ( 28225793 )
2017
6
BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells. ( 28947954 )
2017
7
Study of the TP53 codon 72 polymorphism in oral cancer and oral potentially malignant disorders in Argentine patients. ( 28459200 )
2017
8
Detection of clinically relevant copy number alterations in oral cancer progression using multiplexed droplet digital PCR. ( 28928368 )
2017
9
Hypermethylation of IFN-I^ in oral cancer tissues. ( 28091876 )
2017
10
Prognostic modeling of oral cancer by gene profiles and clinicopathological co-variables. ( 28938638 )
2017
11
Evolution of oral cancer treatment in an andalusian population sample: Rehabilitation with prosthetic obturation and removable partial prosthesis. ( 28936292 )
2017
12
Combinations of SERPINB5 gene polymorphisms and environmental factors are associated with oral cancer risks. ( 28339463 )
2017
13
Hyaluronan synthase 3 mediated oncogenic action through forming inter-regulation loop with tumor necrosis factor alpha in oral cancer. ( 28107185 )
2017
14
Patient-reported quality of life outcomes following treatment for oral cancer. ( 28943022 )
2017
15
Single nucleotide polymorphisms in an Indian cohort and association of CNTN4, MMP2 and SNTB1 variants with oral cancer. ( 28595731 )
2017
16
Survival after surgery for oral cancer: a 30-year experience. ( 28918183 )
2017
17
May High MMP-2 and TIMP-2 Expressions Increase or Decrease the Aggressivity of Oral Cancer? ( 27853937 )
2017
18
Quantitative prediction of oral cancer risk in patients with oral leukoplakia. ( 28545021 )
2017
19
Positron Emission Tomographic Imaging Elucidates the Complex Relationship Between Glucose Uptake and Tissue Blood Flow Mechanism in Squamous Cell Oral Cancer Patients. ( 28934176 )
2017
20
Population-based screening program for reducing oral cancer mortality in 2,334,299 Taiwanese cigarette smokers and/or betel quid chewers. ( 28055109 )
2017
21
In Vitro Growth of Human Keratinocytes and Oral Cancer Cells into Microtissues: An Aerosol-Based Microencapsulation Technique. ( 28952522 )
2017
22
Nanoparticle delivery of Wnt-1 siRNA enhances photodynamic therapy by inhibiting epithelial-mesenchymal transition for oral cancer. ( 28070573 )
2017
23
Expression profiling of long non-coding RNA identifies linc-RoR as a prognostic biomarker in oral cancer. ( 28443494 )
2017
24
Role of Monocyte Count and Neutrophil-to-Lymphocyte Ratio in Survival of Oral Cancer Patients. ( 28050203 )
2017
25
Impacts of survivin and caspase-3 on apoptosis and angiogenesis in oral cancer. ( 28927146 )
2017
26
Iodinated chlorin p6 copper complex induces anti-proliferative effect in oral cancer cells through elevation of intracellular reactive oxygen species. ( 28918125 )
2017
27
Next-generation Sequencing for microRNA Profiling: MicroRNA-21-3p Promotes Oral Cancer Metastasis. ( 28314265 )
2017
28
PPARI^ targeted oral cancer treatment and additional utility of genomics analytic techniques. ( 27896820 )
2017
29
FADS1 rs174549 Polymorphism May Predict a Favorable Response to Chemoradiotherapy in Oral Cancer Patients. ( 27542551 )
2017
30
Plasma levels of the tissue inhibitor matrix metalloproteinase-3 as a potential biomarker in oral cancer progression. ( 28138307 )
2017
31
Two populations of TSPO binding sites in oral cancer SCC-15 cells. ( 27939322 )
2017
32
Pharmacokinetic-Guided Dosing of New Oral Cancer Agents. ( 28921641 )
2017
33
Reply to GalvALo-Moreira and da Cruz: Saliva biomarkers to complement the visualization-based oral cancer detection. ( 28039437 )
2017
34
A facile gold nanoparticle-based ELISA system for detection of osteopontin in saliva: Towards oral cancer diagnostics. ( 28917507 )
2017
35
Interventions for treating oral leukoplakia to prevent oral cancer. ( 28537153 )
2017
36
Variations in oral microbiota associated with oral cancer. ( 28924229 )
2017
37
Combined effect of genetic polymorphisms of AURKA and environmental factors on oral cancer development in Taiwan. ( 28152093 )
2017
38
The emerging role of long noncoding RNAs in oral cancer. ( 27989708 )
2017
39
Chemoprevention of oral cancer in leukoplakia patients: A systematic review and meta-analysis. ( 28924285 )
2017
40
Epigenetic therapy regulates the expression of ALDH1 and immunologic response: Relevance to the prognosis of oral cancer. ( 28939082 )
2017
41
Awareness and Knowledge of Oral Cancer among Siamese Ethnic Group in Tumpat, Kelantan. ( 28951689 )
2017
42
Overexpression of KAI1/CD82 suppresses inA vitro cell growth, migration, invasion and xenograft growth in oral cancer. ( 28260006 )
2017
43
Referrals to dentists by GPs could delay diagnosis of oral cancer. ( 28073743 )
2017
44
Syngeneic Mouse Models of Oral Cancer are Effectively Targeted by anti-CD44-based NIR-PIT. ( 28923838 )
2017
45
Roe Protein Hydrolysates of Giant Grouper (Epinephelus lanceolatus) Inhibit Cell Proliferation of Oral Cancer Cells Involving Apoptosis and Oxidative Stress. ( 27195297 )
2016
46
Polyphyllin G induces apoptosis and autophagy cell death in human oral cancer cells Phytomedicine 23 (2016) 1545-1554. ( 28040307 )
2016
47
Amplification and protein overexpression of cyclin D1: Predictor of occult nodal metastasis in early oral cancer. ( 27653309 )
2016
48
TC2 C776G polymorphism studies in patients with oral cancer in the Polish population. ( 28155977 )
2016
49
Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation. ( 27155849 )
2016
50
Oral cancer: A reasonable postulation. ( 27173687 )
2016

Variations for Oral Cancer

Cosmic variations for Oral Cancer:

9 (show top 50) (show all 620)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM3724309 ZNF536 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1935G>C p.Q645H 5
2 COSM10645 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.527G>T p.C176F 5
3 COSM44894 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.874A>T p.K292* 5
4 COSM43592 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.395A>T p.K132M 5
5 COSM45615 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.776A>G p.D259G 5
6 COSM10659 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.817C>T p.R273C 5
7 COSM11133 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>C p.C242S 5
8 COSM10646 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>A p.C242Y 5
9 COSM10662 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 5
10 COSM10724 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>C p.R280T 5
11 COSM45248 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.805A>T p.S269C 5
12 COSM10727 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.438G>A p.W146* 5
13 COSM43606 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.734G>A p.G245D 5
14 COSM10988 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.772G>A p.E258K 5
15 COSM44633 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.583A>T p.I195F 5
16 COSM45135 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.673-1G>T p.? 5
17 COSM11677 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.925C>T p.P309S 5
18 COSM11166 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.406C>T p.Q136* 5
19 COSM10859 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.814G>T p.V272L 5
20 COSM10958 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.797G>T p.G266V 5
21 COSM10758 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 5
22 COSM44821 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.412G>A p.A138T 5
23 COSM44335 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.958A>T p.K320* 5
24 COSM43708 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.422G>A p.C141Y 5
25 COSM45636 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.934A>T p.T312S 5
26 COSM11066 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.578A>T p.H193L 5
27 COSM43564 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.708C>A p.Y236* 5
28 COSM10992 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.844C>G p.R282G 5
29 COSM10768 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.535C>T p.H179Y 5
30 COSM10648 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.524G>A p.R175H 5
31 COSM43714 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.836G>A p.G279E 5
32 COSM10812 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.722C>T p.S241F 5
33 COSM10660 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.818G>A p.R273H 5
34 COSM45607 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.676G>A p.G226S 5
35 COSM45794 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.421T>G p.C141G 5
36 COSM44126 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.507G>A p.M169I 5
37 COSM11073 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1024C>T p.R342* 5
38 COSM44338 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.845G>A p.R282Q 5
39 COSM44233 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.840A>C p.R280S 5
40 COSM10905 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.451C>T p.P151S 5
41 COSM10738 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.542G>A p.R181H 5
42 COSM10739 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.481G>A p.A161T 5
43 COSM44220 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.417G>T p.K139N 5
44 COSM45077 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.390C>T p.L130L 5
45 COSM10654 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.637C>T p.R213* 5
46 COSM44218 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.536A>C p.H179P 5
47 COSM10672 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.577C>T p.H193Y 5
48 COSM45612 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.685T>C p.C229R 5
49 COSM10889 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.536A>G p.H179R 5
50 COSM10790 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.455C>T p.P152L 5

Copy number variations for Oral Cancer from CNVD:

7 (show top 50) (show all 92)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 16000 1 120982663 144003083 Loss Oral cancer
2 18683 1 147134204 147499075 Loss Oral cancer
3 22566 1 167493797 167507911 Loss NME7 Oral cancer
4 25915 1 195026732 195048237 Gain Oral cancer
5 25916 1 195026732 195104236 Gain Oral cancer
6 30920 1 246713386 246852155 Loss Oral cancer
7 35162 1 604268 4312064 Gain Oral cancer
8 41154 10 138235 42150788 Loss Oral cancer
9 42635 10 37475290 37508431 Loss Oral cancer
10 43408 10 46396192 46516611 Loss Oral cancer
11 48616 11 101407278 102165885 Gain Oral cancer
12 49060 11 102611683 110151240 Loss Oral cancer
13 50726 11 119044645 133316524 Loss Oral cancer
14 52672 11 186966 2789993 Gain Oral cancer
15 55431 11 52900000 134452384 Gain Oral cancer
16 56752 11 60970713 78077527 Gain Oral cancer
17 58595 11 68654476 70150073 Gain Oral cancer
18 79103 13 6365 44752 Loss Oral cancer
19 82813 14 15600000 106368585 Gain Oral cancer
20 83220 14 19560721 22142166 Gain Oral cancer
21 83591 14 21538460 22005864 Gain Oral cancer
22 85535 14 48265939 80627188 Gain Oral cancer
23 88199 14 87604117 106349785 Gain Oral cancer
24 89600 15 18741744 19805989 Loss Oral cancer
25 89601 15 18741744 20060090 Gain Oral cancer
26 101423 16 36766 2592859 Gain Oral cancer
27 106087 16 85963377 88690615 Gain Oral cancer
28 118416 17 77385789 78462808 Gain Oral cancer
29 120365 18 24990733 76110993 Loss Oral cancer
30 124096 19 1 28500000 Gain Oral cancer
31 127007 19 232109 258746 Gain Oral cancer
32 133960 19 8275 236875 Loss Oral cancer
33 136827 2 133504494 133812256 Loss NCKAP5 Oral cancer
34 144179 2 242501268 242717042 Gain Oral cancer
35 150414 20 1 27100000 Gain Oral cancer
36 151218 20 18609 5869816 Gain Oral cancer
37 151741 20 24728423 25680524 Gain Oral cancer
38 152139 20 29436566 62363603 Gain Oral cancer
39 155361 20 55096989 59483462 Gain Oral cancer
40 155973 20 59483462 62194881 Gain Oral cancer
41 160312 22 134684 14797037 Loss Oral cancer
42 164561 22 37689087 37715408 Loss Oral cancer
43 166146 3 1 91700000 Deletion Oral cancer
44 166162 3 1 91700000 Loss Oral cancer
45 167591 3 121355348 144551988 Gain Oral cancer
46 169747 3 145187343 199379595 Gain Oral cancer
47 171086 3 163941201 164138371 Loss Oral cancer
48 172647 3 185019156 185896384 Gain Oral cancer
49 175342 3 39095 9150490 Loss CHL1 Oral cancer
50 175343 3 39095 9150490 Loss GRM7 Oral cancer

Expression for Oral Cancer

Search GEO for disease gene expression data for Oral Cancer.

Pathways for Oral Cancer

Pathways related to Oral Cancer according to GeneCards Suite gene sharing:

(show all 38)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.33 CASP3 CCND1 EGFR MMP2 MMP9 PTGS2
2
Show member pathways
12.62 CYP1A1 GSTM1 GSTM3 GSTT1 PTGS2
3
Show member pathways
12.51 CASP3 CCND1 CDH1 CDKN2A EGFR RARB
4
Show member pathways
12.47 CASP3 CDH1 EGFR TP53
5 12.45 CASP3 CCND1 CDKN2A EGFR MMP9 PTGS2
6
Show member pathways
12.32 CASP3 CCND1 CDKN2A TP53
7 12.32 CCND1 CDH1 CDKN2A TP53
8 12.26 CASP3 CCND1 EGFR MMP2 MMP9 TP53
9 12.25 CASP3 CCND1 CDKN2A TP53
10 12.25 CASP3 CCND1 CDH1 CDKN2A EGFR MMP2
11 12.11 CASP3 CCND1 CDH1 EGFR TP53
12 12.02 GSTM1 GSTM3 GSTT1 MMP2 MMP9 TP53
13 11.98 CASP3 CCND1 CDH1 EGFR MMP2 MMP9
14 11.95 CCND1 MMP2 MMP9 PTGS2 TP53
15 11.93 CCND1 CDKN2A EGFR TP53
16 11.88 CASP3 CCND1 EGFR MMP9 PTGS2 TP53
17 11.79 MMP2 MMP9 PTGS2
18 11.78 CASP3 CCND1 PTGS2 RARB TP53
19 11.77 CCND1 CDH1 MMP2 MMP9
20
Show member pathways
11.74 CYP1A1 GSTM1 GSTT1
21 11.73 CCND1 GSTM1 PTGS2
22 11.68 CASP3 EGFR MMP2 MMP9
23 11.66 CASP3 EGFR MMP2 MMP9
24 11.64 EGFR SLC7A5 TP53
25
Show member pathways
11.64 CCND1 MMP2 MMP9 PTGS2
26 11.6 EGFR MMP2 MMP9
27 11.6 CASP3 CDKN2A GSTM1 GSTM3 GSTT1 TP53
28 11.58 CASP3 MMP9 PTGS2
29
Show member pathways
11.58 CCND1 EGFR MMP2 MMP9
30 11.54 CASP3 CCND1 TP53
31 11.52 CASP3 CCND1 PTGS2 TP53
32 11.48 CYP1A1 EGFR PTGS2
33 11.47 CYP1A1 EGFR SLC7A5
34 11.47 CCND1 CDKN2A EGFR MMP2 TP53
35 11.33 KRT19 PTGS2 TP53
36 11.31 CCND1 MMP2 MMP9
37 11.13 CYP1A1 GSTM1 GSTT1
38 11.03 CCND1 CDH1 CDKN2A EGFR MMP2 MMP9

GO Terms for Oral Cancer

Biological processes related to Oral Cancer according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.91 CASP3 CCND1 CDH1 CYP1A1 PTGS2
2 negative regulation of apoptotic process GO:0043066 9.88 CASP3 EGFR MMP9 RARB TP53
3 positive regulation of protein phosphorylation GO:0001934 9.84 CCND1 CDK2AP1 EGFR MMP9
4 liver development GO:0001889 9.78 CCND1 CYP1A1 EGFR
5 extracellular matrix disassembly GO:0022617 9.77 CDH1 MMP2 MMP9
6 response to glucocorticoid GO:0051384 9.75 CASP3 CCND1 PTGS2
7 response to estrogen GO:0043627 9.74 CCND1 GSTM3 KRT19
8 glutathione metabolic process GO:0006749 9.72 GSTM1 GSTM3 GSTT1
9 embryo implantation GO:0007566 9.7 MMP2 MMP9 PTGS2
10 response to estradiol GO:0032355 9.67 CASP3 CCND1 EGFR PTGS2
11 response to antibiotic GO:0046677 9.63 CASP3 CYP1A1 TP53
12 positive regulation of apoptotic process GO:0043065 9.63 CASP3 CDKN2A MMP9 PTGS2 RARB TP53
13 replicative senescence GO:0090399 9.6 CDKN2A TP53
14 mitotic G1 DNA damage checkpoint GO:0031571 9.58 CCND1 TP53
15 xenobiotic catabolic process GO:0042178 9.56 GSTM1 GSTM3
16 response to X-ray GO:0010165 9.5 CASP3 CCND1 TP53
17 nitrobenzene metabolic process GO:0018916 9.49 GSTM1 GSTM3
18 response to UV-A GO:0070141 9.43 CCND1 EGFR
19 glutathione derivative biosynthetic process GO:1901687 9.43 GSTM1 GSTM3 GSTT1
20 cellular detoxification of nitrogen compound GO:0070458 9.4 GSTM1 GSTM3
21 response to organic cyclic compound GO:0014070 9.35 CASP3 CCND1 CYP1A1 EGFR PTGS2
22 response to organic substance GO:0010033 9.02 CASP3 CCND1 CDH1 CYP1A1 PTGS2

Molecular functions related to Oral Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex binding GO:0032403 9.67 CASP3 CCND1 KRT19 RARB
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.32 CASP3 CDKN2A
3 glutathione binding GO:0043295 9.26